Programmed cell death 1 (PD-1) inhibitors are first- and second-line treatments for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) (1, 2). This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.